Methods for detecting contaminants in solutions containing glucose polymers

Patent metadata

Field	Value
Publication number	US-9494576-B2
Application number	US-201214110569-A
Country	US
Kind code	B2
Filing date	Apr 6, 2012
Priority date	Apr 8, 2011
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

The invention relates to a method for detecting contaminants of glucose polymers, said contaminants being capable of acting in synergy with one another so as to trigger an inflammatory reaction, characterized in that it comprises an in vitro inflammatory response test using modified cell lines.

First claim

The invention claimed is:

1. A method for detecting pro-inflammatory contaminants in a composition comprising glucose polymers, the method comprising:
contacting a plurality of cell lines with the composition comprising glucose polymers, each of the plurality of cell lines expressing one or more Toll-Like Receptors (TLRs) or Nucleotide-binding Oligomerization Domain-containing protein-like receptors (NOD), wherein the plurality of cell lines comprises:
a) a cell line expressing TLR2 and containing a reporter gene encoding a secreted form of alkaline phosphatase under the direct control of the TLR2 signaling pathway;
b) a cell line expressing NOD2 and containing a reporter gene encoding a secreted form of alkaline phosphatase under the direct control of the NOD2 signaling pathway;
c) a cell line expressing TLR4 and containing a reporter gene encoding a secreted form of alkaline phosphatase under the direct control of the TLR4 signaling pathway;
d) a cell line expressing TLR2, TLR4 and NOD2 and containing a reporter gene encoding a secreted form of alkaline phosphatase under the direct control of the TLR2, TLR4 or NOD2 signaling pathway; and
e) a negative control cell line;

measuring activity of the secreted form of alkaline phosphatase; and identifying, based on the higher alkaline phosphatase activity in any of the cell lines a) to d) compared to the negative control, the presence, in the composition, of proinflammatory contaminants capable of activating one or more innate immunity receptors and triggering an inflammatory reaction.

2. The method of claim 1 , wherein the composition comprising glucose polymers is for peritoneal dialysis, for enteral feeding, for parenteral feeding or for feeding newborn babies.

3. The method of claim 1 , wherein the method further comprises:
contacting a macrophage cell line with the composition of glucose polymers that may contain pro-inflammatory contaminants;
measuring the production of Chemokine (C-C motif) ligand 5 (RANTES) by the macrophage cell line; and
identifying, based on the production of RANTES, the presence, in the composition comprising glucose polymers, of contaminants capable of triggering an inflammatory reaction.

4. The method of claim 3 , wherein a molecule chosen from muramyl dipeptide (MDP), L18-MDP, glycolyl-MDP, formyl-Met-Leu-Phe or lipopolysaccharide (LPS) is added to the composition comprising glucose polymers.

5. The method of claim 4 , wherein MDP or LPS is added to the composition comprising glucose polymers.

6. The method of claim 3 , wherein the production of RANTES is measured under one or more of the following conditions:
the macrophage cell line is used at a density of between 0.5×10 6 and 1×10 6 cells/ml; and/or
the glucose polymer concentration in the culture medium is less than 50 mg/ml; and/or
the RANTES production is measured after 20 h of contacting; and/or
MDP is added to the composition comprising glucose polymers at a concentration of between 1 and 100 μg/ml.

7. The method of claim 3 , said method comprising detecting glucose polymer contamination with peptidoglycans (PGNs) and/or LPS.

8. The method of claim 1 , wherein said method detects contamination with MDPs, wherein the detection of MDPs is performed with the cell line expressing NOD2 and containing a reporter gene encoding an alkaline phosphatase under the direct control of the NOD2 signaling pathway.

9. The method of claim 1 , wherein said method detects contamination with PGNs, wherein the detection of PGNs is performed with the cell line expressing TLR2 and containing a reporter gene encoding an alkaline phosphatase under the direct control of the TLR2 signaling pathway.

10. The method of claim 1 , wherein the composition comprising glucose polymers has a polymer concentration from 5 to 50 mg/ml.

11. The method of claim 1 , wherein said method comprises:
a step of treating the composition comprising glucose polymers with a mutanolysin prior to said contacting with the plurality of cell lines; or
a step of filtering the composition comprising glucose polymers with a cut-off threshold of between 30 kD and 150 kD and contacting the filtrate with the plurality of cell lines, and optionally, comparing the results of the filtrate polymers contacted with the plurality of cell lines with the results of an unfiltered composition comprising glucose polymers contacted with the plurality of cell lines.

12. The method of claim 1 , wherein said method also comprises a step of identifying or quantifying the contaminant(s) capable of triggering an inflammatory reaction.

13. The method of claim 1 , wherein the method comprises quantifying the proinflammatory contaminant, wherein the contaminant is peptidoglycans (PGNs), and wherein the quantification of PGNs is performed with the cell line expressing TLR2 and containing the reporter gene encoding the secreted form of alkaline phosphatase under the direct control of TLR2 signaling pathway.

14. The method of claim 13 , wherein said method comprises a step of treating the composition comprising glucose polymers with a mutanolysin, a step of incubating mutanolysin treated and untreated glucose polymer compositions with said plurality of cell lines, and a step of quantifying the PGNs.

15. The method of claim 1 , wherein said plurality of cell lines comprise:
a) an HEK293 cell line that stably co-expresses the human TLR2 and NF-κB-inducible secreted embryonic alkaline phosphatase (SEAP);
b) an HEK293 cell line that stably co-expresses the human NOD2 and NE-KB-inducible SEAP;
c) an HEK293 cell line that stably co-expresses the human TLR4 and NF-κB-inducible SEAP;
d) a RAW 264.7 cell line that stably express SEAP gene inducible by NF-κB and activator protein 1 (AP-1) transcription factor; and
e) an HEK293 cell line expressing SEAP gene under the control of the interleukin-12 (IL-12) p40 minimal promoter fused to five NF-κB and AP-1 binding sites.

16. The method of claim 3 , wherein said macrophage cell line is THP-1.

Assignees

• Lanos Pierre
• Hacine-Gherbi Hela
• Allain Fabrice
• Carpentier Mathieu
• Denys Agnes
• Roquette Freres

Inventors

• Lanos Pierre
• Hacine-Gherbi Hela
• Allain Fabrice
• Carpentier Mathieu
• Denys Agnes

Classifications

• A61P7/08

  Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) · CPC title

• C12Q1/22 Primary

  Testing for sterility conditions · CPC title

• G01N33/5055 Primary

  involving macrophages · CPC title

• G01N33/5047 Primary

  Cells of the immune system · CPC title

• C12Q1/42

  involving phosphatase · CPC title